Wednesday, February 08, 2006
Picture this: A man sits on an ergonomically designed chair that reduces fatigue, and clicks away on a key-pad technologically enhanced to ’sense’ the touch of his fingers enough to type the letter just once (not twice) on his laptop screen, which has the right resolution of horizontal and vertical lines to perfect the illumination on his screen so that his eyes are better protected. He finishes typing, checks his spelling and grammar on a word processing software, which has a thousand features, and saves his document on his miniscule thumb-drive, using a high-speed USB port through a giga-powered processor. He e-mails it to his publisher, who will soon use the full power of the available technology to get the article to the readers with the shortest elapsed time and best quality print or even a web-cast. He sits back and sips his drink, which has sugar-free ‘Equal,’ non-dairy creamer, and de-caffeinated coffee. He has just written an article criticizing Intellectual Property Rights, (IPRs), patents and innovations – ironically, the key drivers which made all of the above possible. He says patent holders are profiteers. He says R&D creates more wealth for the wealthy. He says as long as there are patents and Intellectual Property Rights, the poor will suffer. He takes his tablets for blood pressure and diabetes. He looks at his screen once again. Somehow, his criticism lacks conviction. He seems to be biting the hand that feeds him. Next time he wants to criticize innovation, inventions, and patent rights, he should go back to his cave and engrave it on the walls of his cave.
PUNISH THE GOOD GUYS?
Whether our critic is working on the laptop, or travelling in his car with turbo power (>20 patents), and fuel injection (>50 patents), protected by airbags (>50 patents), or sitting in his office with air-conditioning having plasma cluster (>26 patents), or using his Canon (31,388 patents) photo copier, or watching Hitachi (32,834 patents) TV, we are increasingly becoming aware that inventions, innovations and patent rights improve quality of life. Good! So, we support patent rights, for computers, photocopiers, automobiles, air conditioners, and many more industries, except……except? Except pharmaceuticals! Really? Why is it that all companies that spend money on R&D can recover their investments except pharmaceutical companies? It appears that we discriminating against pharmaceutical companies who discover new drugs. Pharma companies are investing in R&D to save lives and reduce human suffering. So, what if they are trying to make some money from it? The company which invented TV Plasma screen made money from it, and no one created a scene. The company which invented quieter air-conditioners made money from it, and no one made a big noise about it. Should we reward entertainers and punish life-savers? Besides, if pharmaceutical companies don’t benefit from their investments in a drug, they will neither have the incentive nor the resources to invest in the R&D for the next life-saving drug.
R&D is the lifeline of a company. New products are the company’s differentiators. Without innovation, invention and discovery, a company will not be able to stay ahead of competition. Leading companies recognize the value of R&D, and invest heavily in R&D. Specifically, in pharmaceutical industry, it takes about $500 million to $900 million to develop a successful new drug. Obviously, the pharmaceutical company invests this amount to make a profit, not to give away its invention to its competition. It will be silly for Pfizer to give away its block-buster drug to Merck for free after spending a billion on R&D. Then, why do we think Pfizer should give it away to a company in India? Competition is competition, be it in USA or in Antarctica. Actually, no company in India has asked Pfizer to give away its block bluster drug without any licensing arrangement. But then, re-engineering the drug, and manufacturing and selling it without license amounts to the same, if not worse.
BUSINESS OR CHARITY?
I will meet the CEO of Pfizer. I invite any interested company in India or any other country to join hands with me. I will personally convince Mr. Henry McKinnell, and I hope that he will agree. The deal will be this: Pfizer will allow unrestricted use of its patent without royalties or license or any payment of any kind by the Indian pharmaceutical company. In return, the Indian company will manufacture and sell the drug in their home country to the patients “at cost.” There will be no profit for Pfizer, and no profit for the Indian company. Deal?
If we are concerned about patient’s lives and well-being, then let us work for their cause. Let all the pharmaceutical companies of the world come together and form one big charitable organization. Red Cross can eat its heart out. Generic medicines will be distributed free, because there are no patents involved anyway. Marketing managers’ incentive compensation will be based on lives saved, not on sales booked. Okay, we can all wake up now. In reality, businesses do serve charitable causes, but their philanthropy department is very far from their R&D department, and its going to be that way until their R&D managers prove accurately that the end of the world is nigh.
THERE ARE MANY WAYS TO SKIN A CAT!
We need not target the pharmaceutical companies. There can be other ways to make drugs cheaper for patients.
Government Can Fund R&D
If government sponsors R&D of a drug which targets a certain disease, the equation will change completely. The government, in association with private companies who have the required expertise, can jointly pursue a drug which can cure a life-threatening disease. If the government is very vocal about public health, this is one good way to put their money where their mouth is.
Government Can Subsidize the Cost
Another way the government can help is by subsidizing the cost of life-saving drugs. If the government can subsidize the price of rice, petrol, etc., it can also subsidize the cost of life-saving drugs. But, may be there are not enough dying patients to form a ‘votebank,’ or may be, the cost of drug subsidy versus number of vote generation does not seem to be a viable proposition.
NPPA Should be More Aggressive
National Pharmaceutical Pricing Authority (NPPA) should aggressively follow the agenda of lowering price of life-saving drugs through participation in technology transfer or licensing arrangements. India is a big market, and foreign pharma companies will definitely fall in line when new drug pricing is seen to be connected with the purchasing arrangements on the generics.
Compulsory Licensing Should be Invoked
A serious approach to compulsory licensing with a sincere resolve can be a good deterrent to over-pricing of drugs. The government should force licensing whenever it sees a foreign company unwilling to consider Third World pricing.
Government Can Acquire the Patents
The central government can acquire a patent/invention for a public purpose, paying a suitable negotiated compensation. What is needed for this is a conclusive argument that a certain drug is essential for life-saving and the suffering is of certain magnitude.
India Can Develop its Own New Drugs
India can use its cost advantage to develop new drugs at a cheaper rate and a faster pace. In this manner, India will soon have its own, patented new drugs to dominate the global markets in research and new drug discoveries, too. According to Syngene, India’s highly successful contract research firm for pharmaceuticals, the cost of doing R&D in India is five times lower than the cost involved in new drug discovery in a developed country. The launch of a new molecule in India costs only about $100-200 million as against the US, where it is estimated that the average cost to develop a successful new drug is nearly $500-900 million (sometimes close to $1 billion). New drugs developed by India can be priced lower for Indian consumption.
Indian pharmaceutical industry has already embarked on the journey to benefit from the product patents. As opposed to earlier, when Indian companies invested only around 1% on R&D, they are now investing huge amounts on R&D. In 2003-04, the top 10 Indian pharma companies spent about $400 million on R&D. The shift in the patent regime from process patents to product patents will prove to be a blessing in disguise for India in the long run, as it will encourage more Indian pharma companies to focus on R&D and compete with their global counterparts. As Dr. Reddy, Chairman DRL, says, “Excelling in the basic business operations will be necessary, but not sufficient. To maintain a long-term presence in the global pharmaceuticals markets and to grow profitably will require companies to be even more focused on R&D and creation of successful IPRs [Intellectual Property Rights].”1
JUSTICE, EQUALITY … AND PATENTS!
Contrary to popular belief, especially in the pharmaceutical industry, no harm was done to India in the Patents (Third Amendment) Act of 2005. The Act neither says that pharmaceutical patents will only be granted to foreign companies, nor does it say that Indian companies will be disallowed to conduct R&D, or that there will be any discrimination against India. On the contrary, it said that India will have equal rights and equal opportunities – equal to USA, and equal to all countries of the world. India can invest in R&D, and the actual spending in India will be lower than that of USA. India can sell their new drugs in the whole world and have patent protection in most countries. India will have full legal protection of its rights which are now equal to USA and all other countries. So, why this hue and cry? Since when has equality become such a cruel punishment and a dreadful nightmare? Why is India trying to show equality as unjust or unfair? Or, is India unsure of its quality in equality? I would have thought that India deserved to be equal. In fact, the ‘equal’ position is always the start of a race. And, if India does it right, it can win this race!
© 2005, iPrex Solutions. All Rights Reserved.
1. “What’s Driving India’s Rise as an R&D Hub?” http://www.knowledge.wharton.upenn.edu.
REFERENCES & BIBLIOGRAPHY
1. “Beximco Raises $21m Via Institutional Placing,” http://www.in-pharmatechnologist.com, October 17, 2005.
2. Naik, SD, “New Patent Regime – Discovering New Challenges,” http://www.thehindubusinessline.com, April 12, 2005.
3. Panchal, Salil, “Patents Era: How Will Pharma Firms Cope?” http://www.ushome.rediff.com, April 7, 2005.
4. “Drug Patent: A Viagra for Indian Pharmaceutical Industry,” http://www.deccanherald.com, April 4, 2005.
5. “Bangladesh Eyes Huge Medicine Market in Africa,” http://www.independent-bangladesh.com, March 29, 2005.
6. “Indian Patent Law Could Prove a Tonic For Bangladesh Drug Firms,” http://www.aegis.com, March 27, 2005.
7. “World Pharma Markets Still Slowing down,” http://www.drugresearcher.com, March 10, 2005.
8. Basu, Paroma, “International Patent Law – Boon or Bane of Biotech?” http://www.nature.com, January 7, 2005.
9. “Brazil Generics Market Report,” http://www.espicom.com, September 2004.
10. Balakrishnan, Reghu, “Carnival Days Ahead for Indian Pharma Cos in Brazil,” http://www.pharmabiz.com, August 19, 2004.
11. “Banking on Generic Drugs,” http://www.pharmabiz.com, August 19, 2004.
12. Kulkarni, Jayashri, “Brazilian Pharma Market: A Veritable Goldmine for Generic Players?” http://www.pharmabiz.com, August 19, 2004.
13. “Thailand: American Bullying Puts Pharmaceutical Company Profits Before the Health of Millions,” http://www.oxfamgb.org, October 2002.
14. “Pharmaceuticals – Brazilian Market,” http://www.indiaconsulate.org.br, June 2002.
15. Gross, Ames, “New Regulatory Trends in Thailand’s Pharmaceutical Market,” http://www.pacificbridgemedical.com, March 1999.
16. “Research Overview,” http://www.the-infoshop.com.
17. “Overview of Chinese Pharmaceutical Industry,” http://www.en.wikipedia.org.
18. “Pharmas,” http://www.heureka.clara.net.
19. “What’s Driving India’s Rise as an R&D Hub?” http://www.knowledge.wharton.upenn.edu.